Showing papers by "Amit M. Oza published in 2004"
TL;DR: The administration of AC with irinotecan reduced the incidence of grade 3 to 4 diarrhea and antidiarrheal medication consumption and increased irinOTecan dose-intensity, and prophylactic AC may have a role in reducing dose-limiting CID and optimizing irinoderm therapy.
Abstract: Purpose The dose-limiting toxicity of irinotecan (CPT-11; Camptosar) is delayed-onset diarrhea, with an incidence at the grade 3 to 4 level of 20% to 35%. SN38, its active moiety, is responsible by a direct effect on mucosal topoisomerase-I. The aim of this study was to assess whether activated charcoal (AC), possibly by adsorbing free lumenal SN38, can reduce irinotecan-induced diarrhea (CID) and optimize its dose-intensity. Patients and Methods Patients with advanced colorectal cancer receiving irinotecan 125 mg/m2 intravenously once a week for 4 weeks every 6 weeks were studied. In cycle 1, patients received irinotecan plus AC (5 mL aqueous Charcodote [1,000 mg AC] plus 25 mL water) given the evening before the irinotecan dose and then tid for 48 hours after the dose. In cycle 2, no AC was given. National Cancer Institute Common Toxicity Criteria diarrhea grade, irinotecan dose-intensity, and loperamide consumption were recorded prospectively in both cycles. Results Twenty-eight patients had completed ...
71 citations
TL;DR: A 15-year-old girl who presented with a painful pelvic mass underwent a laparotomy with tumor resection and was recommenced on Gleevac in an effort to prevent recurrences, supporting the concept of targeted molecular therapy in patients with c-kit-positive FATWO tumors.
Abstract: Female adnexal tumors of probable wolffian origin (FATWOs) are rare tumors arising in the broad ligament from the remnants of the mesonephric duct. We report a case of recurrent disease. A 15-year-old girl who presented with a painful pelvic mass underwent a laparotomy with tumor resection. Pathology findings confirmed a FATWO. The tumor recurred within 2 years and was treated with multiple chemotherapy regimens, including a platinum-based drug, and surgery for progressive disease. The tumor was positive for c-kit oncogene (CD 117). Gleevac therapy, a tyrosine kinase inhibitor, was prescribed, and she developed severe persistent lower abdominal pain 2 months later. She underwent a hysterectomy and debulking of retroperitoneal masses. Pathology showed evidence of tumor necrosis, suggesting a possible beneficial effect, and she was recommenced on Gleevac in an effort to prevent recurrences. She is currently asymptomatic, without evidence of disease 10 months after surgery, continuing on Gleevac therapy. FATWOs are very rare tumors. Most cases are benign but have the potential to recur and metastasize. There is limited knowledge about the optimal treatment for this neoplasm. Our patient's favorable response to Gleevac therapy supports the concept of targeted molecular therapy in patients with c-kit-positive FATWO tumors.
40 citations
TL;DR: The 50-mg dosing regimen was better tolerated than the 200-mg arm, with gastrointestinal AEs being most common toxicities, and no associations were apparent between baseline tumor erbB expression profiles and PFS or OS.
Abstract: 5054 Background: Ovarian cancer that is refractory to platinum-based therapies is a therapeutic challenge, particularly in the setting of erbB-1 and -2 receptor over- expression. CI-1033 is an irreversible, 4-anilinoquinazoline pan-erbB tyrosine kinase inhibitor with activity in a wide variety of human tumor xenografts, particularly erbB+ tumors including ovarian SK-OV-3. Methods: This study evaluated 50- and 200mg doses of CI-1033, given daily for 21 days repeated every 28 until disease progression in pts with platinum-refractory ovarian cancer. Primary eligibility criteria included disease progression following platinum therapy, measurable disease, and Karnofsky Performance Status (KPS) of 60–100. Baseline tumor erbB receptor profiles were determined by IHC staining retrospectively in 56 of the 105 pts. Endpoints included 1-yr progression-free survival (PFS) and overall survival (OS). Results: Between January and May of 2002, 105 patients were enrolled. Baseline characteristics were balanced between bot...
21 citations
8 citations
TL;DR: Assessment of the activity of PS341 in patients with metastatic colorectal cancer who had received no more than 1 prior line of chemotherapy with irinotecan (or oxaliplatin)/5 fluorouracil for metastatic disease results in significant regression in a human colon cancer xenograft model.
Abstract: 3109 Background: The ubiquitinin-proteosome proteolytic pathway regulates the metabolism of critical proteins involved in the cell cycle, apoptosis and metastasis such as p53, p21, p27 and NFκB. PS341(Bortezomib; Velcade) is a specific and selective inhibitor of the 26S proteosome. PS341 results in significant regression in a human colon cancer xenograft model. Methods: This phase II study aimed to assess the activity of PS341 in patients with metastatic colorectal cancer who had received no more than 1 prior line of chemotherapy with irinotecan (or oxaliplatin)/5 fluorouracil for metastatic disease. Primary endpoints were objective response or disease stabilization; with a multinomial stopping rule and secondary endpoints included assessment of molecular changes with therapy, survival and tolerability. PS 341 at a dose of 1.3mg/m2/day was administered as an intravenous bolus days 1,4,8 and 11 of a 21 day cycle. Tumor response was assessed by RECIST criteria every 2 cycles. Tumor biopsies were performed p...
7 citations
2 citations